Please use this identifier to cite or link to this item:
Blankart, Katharina Elisabeth
Stargardt, Tom
Year of Publication: 
[Journal:] Health Economics [ISSN:] 1099-1050 [Volume:] [Issue:] [Pages:] n/a-n/a
Payers are increasingly calling for the value of new drugs to be measured explicitly. We analyze how the availability of drug quality ratings by health technology assessment (HTA) agencies affects the adoption of new drugs by physicians in Germany. We combine data from drug quality ratings, promotional spending, and a physician panel. In a latent utility model, time to adoption is specified as a function of quality rating, promotional spending by manufacturers, and physician‐specific variables. As expected, drugs with a positive rating were adopted faster (p < 0.001) than those without. However, our results suggest that it was the publication of the quality rating itself that affected adoption. Indeed, before a quality rating was published, drugs that went on to receive a positive quality rating were not adopted significantly faster than drugs that went on to receive a negative quality rating. In contrast, after the publication of the HTA quality rating, drugs with a positive rating were adopted significantly faster than those without (p < 0.05). The per physician value of a positive quality rating was EUR 393.50. Our results suggest that there are returns from HTAs beyond their use in price negotiations.
duration analysis
government policy
information and knowledge
public health
Persistent Identifier of the first edition: 
Creative Commons License:
Document Type: 
Document Version: 
Published Version

Files in This Item:

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.